In short, γδ TCR-enhanced CAR T-cell therapy for metastatic prostate cancer contributes essential ideas to the value of this approach by revealing lasting interactions between γδ TCRs and PSCA through computational software. Nonetheless, in-silico methods have many limitations in accuracy, simulation, and validation that are important to remember before assessing the results. Despite these constraints, this research shows prospective development in improving the efficiency of CAR T-cell therapy, demonstrating the need for joining technology and clinical validations to find progress in cancer treatments.